The Efficacy and Safety of Jaungo, a Traditional Medicinal Ointment, in Preventing Radiation Dermatitis in Patients with Breast Cancer: A Prospective, Single-Blinded, Randomized Pilot Study

Table 1

Patient characteristics.

	Intervention group ()	Control group ()	value
Age (years)
Median (range)	54.1 (46.4–74.2)	50.7 (40.1–70.8)	0.368
Diabetes mellitus
Yes/no	1/14	1/13	0.911
ECOG performance status
0/1	2/13	1/13	0.834
Body mass index (kg/m^2)
Median (range)	23.5 (19.9–32.2)	23.2 (16.6–29.7)	0.162
Breast size^† (cc)
Median (range)	364.8 (208.9–609.2)	372.4 (200.8–568.3)	0.345
Site
Right/left	5/10	5/9	0.874
Histology
Ductal carcinoma	11	11	0.826
Nonductal carcinoma	4	3
T stage
In situ	4	2	0.391
1	6	7
2	5	5
N stage
0	14	13	0.934
1	1	1
Molecular subtypes
Luminal	10	12	0.187
Triple negative	2	1
HER2-positive	3	1
Total RT dose (Gy)
Median (range)	55 (46–61)	58 (46–58)	0.571
Lymph node irradiation
Yes/no	1/14	0/14	0.423
Adjuvant chemotherapy
Yes/no	6/9	5/9	0.721
Concurrent hormone therapy
Yes/no	9/6	10/4	0.627
Concurrent herceptin therapy
Yes/no	1/14	1/13	0.857

Calculated from the clinical target volume (CTV) of the whole breast using the radiotherapy planning computer
ECOG, Eastern Cooperative Oncology Group; HER2, human epidermal growth factor receptor 2; RT, radiotherapy.